Adelaide, South Australia wants to let the secret out, and be known as hub for medical devices, pharmaceuticals, biotechnology, and digital health. It boasts world-class research institutions, such as the University of Adelaide and SAHMRI, fostering innovation and collaboration. The city’s supportive government policies provide incentives, grants, and streamlined regulations for businesses. Adelaide’s skilled workforce, renowned for its expertise in health sciences, offers a talent pool to drive industry growth. Additionally, the city’s strategic location, advanced infrastructure, and strong healthcare ecosystem make it an ideal base for development, manufacturing, and market access, attracting companies in these sectors.
Australian Health Journal spoke to Jo Close, heading the Adelaide arm of MTPConnect about the opportunity its building through its role as the industry growth centre, to help increase commercialisation and collaboration across the sector, optimise the regulatory environment, improving workforce skills and access to markets globally.
One of the companies showing world leading MedTech capabilities arising from Adelaide is Additive Surgical, the first company in Australia to manufacture 3D Printed Titanium novel spinal implant technologies. Its mission is to manufacture the highest quality medical technology in Australia that positively impact the lives of people globally.
Australian Health Journal met with Co-founder and CEO Gibran Maher.
Maher states, “Additive Surgical is committed to supporting Australian innovation and works closely with the Australian clinicians, hospitals, research institutions and universities to innovate and manufacture locally.”
Maher points out the ability to compete is made possible through supportive collaboration with government, research and other enterprises seeking to learn from each other. But to truely compete in international markets, Australia’s needs to further strengthen its sovereign capability.
Currently Australia imports more than 80% of its medical devices. Large multinational companies have very strong market share in Australia and the profits from these companies are largely returned to their international shareholders.
Additive Surgical is committed to manufacturing in Australia, developing intellectual property in Australia and supporting Australian innovation and commercialisation.
You Might also like
-
NSW Medical Device Commercialisation Training Program (MDCTP) Graduation 2019
Cicada Innovations with NSW Health this week hosted the graduation night for the 15 individuals that were part of the NSW Medical Device Commercialisation Training Program (MDCTP).
-
The 2019 John Deeble Lecture and Panel Discussion
The John Deeble Lecture and Panel Discussion was established by the Australian Healthcare and Hospitals Association to commemorate the life and achievements as distinguished scholar, health economist and health policy leader, Prof John Deeble AO.
-
Child Dental Benefits Schedule needing greater awareness
Since its launch in 2014, the Child Dental Benefits Schedule has seen a gradual increase in participation year on year. The impact of COVID-19 and related shutdowns saw participation fall sharply in 2020. Though it increased 2021, the national target of 41% participation was not reached in 2021-2022, with the total (35.4%) more than three percent below 2018 participation rates.
In an opinion segment, Australian Health Journal spoke with Abano Healthcare Group Clinical Director, Dr Fred Calavassy, with over 30 years of clinical experience, about his observations of the Child Dental Benefits Scheme ways to increasing participation rates.